Founder and Chief Technology Officer

Vincent Tadino is ORA’s Chief Technology Officer. He founded ORA in 2006 and currently serves as its President and CTO. Founded in Liege, Belgium, ORA has become a world leader in automated synthesizers for the production of radio-pharmaceuticals, particularly in medical imaging of neurodegenerative diseases (i.e. Alzheimer), as well as in advanced diagnostic of cancer and cardiac diseases.

Prior to founding ORA, Vincent Tadino served as project chief, radiochemistry developer, and quality manager for 7 years in different companies active in PET radiopharmaceutical equipment and production, both in Europe and the USA. He holds, as inventor and/or as co-inventor, seven patents (five of which are in PET chemistry) and is the author of several abstracts/presentations in international congresses.

Vincent Tadino received his PhD, cum laude, in Organic Chemistry at the University of Liège, Belgium, in 1996, and completed a PostDoc research in Organic Chemistry at ISMRA in Caen, France. He was the first to develop a fully automated chemistry of [18F] Fluoro-Choline for a disposable cassette system. He also made several developments for FLT, MPPF and PiB (Pittsburg compound B for Alzheimer diagnostic) tracers.

Through the several Marketing Authorizations (MA), Mutual Recognition Procedures (MRP) and Quality Assurance (QA) manuals drafted for various GMP production facilities in Europe and the U.S., Vincent Tadino is a recognized expert in international regulations for radiopharmaceutical production.